Windtree Therapeutics Inc (WINT) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Windtree Therapeutics Inc (WINT) has a cash flow conversion efficiency ratio of 0.549x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-6.37 Million) by net assets ($-11.60 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. View Windtree Therapeutics Inc share price for real-time trading data and today's change.
Windtree Therapeutics Inc - Cash Flow Conversion Efficiency Trend (1995–2024)
This chart illustrates how Windtree Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Also see market value of Windtree Therapeutics Inc for the company's overall valuation and market capitalisation.
Windtree Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Windtree Therapeutics Inc ranked by their cash flow conversion efficiency. Also see Windtree Therapeutics Inc assets under control for a full breakdown of the balance sheet.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Thai Union Group Public Company Limited
F:THYG
|
0.011x |
|
Arrival
NASDAQ:ARVLF
|
-0.078x |
|
Soosung Innovation Co. Ltd.
KQ:084180
|
0.039x |
|
Ben Thanh Rubber JSC
VN:BRC
|
N/A |
|
PTT OIL+RET.BUS.-FOR-BA10
F:7F8
|
0.185x |
|
Holdco Nuvo Group D.G Ltd. Ordinary Shares
NYSE MKT:NUVO
|
-0.005x |
|
Chicken Soup for the Soul Entertainment, Inc.
NASDAQ:CSSEQ
|
0.001x |
|
DIH Holdings US, Inc. Class A Common Stock
NASDAQ:DHAI
|
0.089x |
Annual Cash Flow Conversion Efficiency for Windtree Therapeutics Inc (1995–2024)
The table below shows the annual cash flow conversion efficiency of Windtree Therapeutics Inc from 1995 to 2024. Review WINT financial flexibility index to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $10.00 Million | $-15.40 Million | -1.541x | +61.12% |
| 2023-12-31 | $3.39 Million | $-13.44 Million | -3.963x | -103.95% |
| 2022-12-31 | $10.01 Million | $-19.45 Million | -1.943x | -243.85% |
| 2021-12-31 | $41.88 Million | $-23.66 Million | -0.565x | -55.24% |
| 2020-12-31 | $69.55 Million | $-25.32 Million | -0.364x | -10.59% |
| 2019-12-31 | $74.94 Million | $-24.66 Million | -0.329x | -42.06% |
| 2018-12-31 | $68.11 Million | $-15.78 Million | -0.232x | -126.33% |
| 2017-12-31 | $-23.92 Million | $-21.05 Million | 0.880x | -24.48% |
| 2016-12-31 | $-28.83 Million | $-33.59 Million | 1.165x | +128.74% |
| 2015-12-31 | $8.27 Million | $-33.50 Million | -4.053x | -89.02% |
| 2014-12-31 | $19.20 Million | $-41.17 Million | -2.144x | -210.09% |
| 2013-12-31 | $58.50 Million | $-40.45 Million | -0.692x | +62.88% |
| 2012-12-31 | $17.65 Million | $-32.88 Million | -1.863x | +89.63% |
| 2011-12-31 | $1.26 Million | $-22.70 Million | -17.957x | -345.86% |
| 2010-12-31 | $6.03 Million | $-24.27 Million | -4.028x | +34.08% |
| 2009-12-31 | $4.49 Million | $-27.41 Million | -6.110x | -110.38% |
| 2008-12-31 | $10.93 Million | $-31.75 Million | -2.904x | -283.16% |
| 2007-12-31 | $38.78 Million | $-29.39 Million | -0.758x | +72.74% |
| 2006-12-31 | $14.32 Million | $-39.83 Million | -2.781x | -67.99% |
| 2005-12-31 | $34.84 Million | $-57.67 Million | -1.655x | -4.74% |
| 2004-12-31 | $21.10 Million | $-33.34 Million | -1.580x | -63.71% |
| 2003-12-31 | $24.30 Million | $-23.46 Million | -0.965x | -6.06% |
| 2002-12-31 | $14.76 Million | $-13.44 Million | -0.910x | -26.31% |
| 2001-12-31 | $17.62 Million | $-12.70 Million | -0.721x | -102.25% |
| 2000-12-31 | $16.44 Million | $-5.86 Million | -0.356x | +73.23% |
| 1999-12-31 | $3.11 Million | $-4.14 Million | -1.331x | +31.49% |
| 1998-12-31 | $3.50 Million | $-6.80 Million | -1.943x | -319.66% |
| 1997-12-31 | $10.80 Million | $-5.00 Million | -0.463x | +64.73% |
| 1996-12-31 | $1.60 Million | $-2.10 Million | -1.313x | -89.00% |
| 1995-12-31 | $3.60 Million | $-2.50 Million | -0.694x | -- |
About Windtree Therapeutics Inc
Windtree Therapeutics, Inc., a biotechnology company, focuses on the development of therapeutics for the treatment of acute cardiovascular diseases. Its lead product candidate is istaroxime, which is in Phase 2b clinical trials for the treatment of acute decompensated heart failure, as well as for the treatment of early cardiogenic shock. The company also develops AEROSURF, an aerosolized KL4 sur… Read more